PKIB

PKIB is an endogenous inhibitor of the cAMP-dependent protein kinase A catalytic subunit (PKA-C) that uses a pseudosubstrate site to engage PKA-C and, together with a leucine-rich nuclear export signal, governs the enzyme's subcellular distribution (PMID:10880337, PMID:19483721). By directly binding PKA-C, PKIB suppresses PKA kinase activity and reduces phosphorylation of substrates such as HSP27 at Ser15/78/82 (PMID:40593489), and it controls nuclear translocation of PKA-C — its knockdown diminishes nuclear PKA-C (PMID:19483721) while its induction drives nuclear PKA-C accumulation and increased CREB phosphorylation (PMID:38030378). Paradoxically, PKIB also enhances PKA-C-mediated phosphorylation of Akt at Ser473, a function demonstrated by in vitro reconstitution with recombinant proteins and by loss of Akt Ser473 phosphorylation on knockdown (PMID:19483721), placing PKIB upstream of PI3K/Akt signaling in driving proliferation, migration, and invasion in cancer and trophoblast cells (PMID:27325557, PMID:32676926). Independently of its PKA-inhibitory pseudosubstrate domain, PKIB binds the cytosolic C-terminus of the zinc receptor GPR39 and enhances its constitutive Gα13/RhoA/SRE signaling, with zinc triggering PKIB dissociation from GPR39 to free it for PKA inhibition in a negative-feedback loop (PMID:24869658). PKIB expression is a regulated node integrating hormonal and nutrient signals: it is induced by HIF1 under chronic hyperglycemia in pancreatic islets, where its disruption improves islet function in obese mice (PMID:25704817), and by GR and MYCN in prostate and bladder cancer contexts (PMID:38030378, PMID:40593489).

1. 2000 Medium

   Established the existence and identity of human PKIB, answering whether a distinct PKI-family inhibitor with both a pseudosubstrate site and a nuclear export signal exists in humans.

   Evidence cDNA cloning, sequence/domain analysis, and Northern blot of the human gene

   PMID:10880337

   Open questions at the time

   • No direct demonstration of PKA inhibition or binding in this study
   • Functional consequences of the nuclear export signal not tested
2. 2009 Medium

   Showed that PKIB physically binds PKA-C and controls its nuclear translocation, defining PKIB as a regulator of PKA-C localization rather than a purely cytosolic inhibitor.

   Evidence Co-immunoprecipitation, siRNA knockdown, and subcellular fractionation/imaging in prostate cancer cells

   PMID:19483721

   Open questions at the time

   • Mechanism by which PKIB directs PKA-C trafficking not resolved
   • Single-lab Co-IP without reciprocal structural validation
3. 2009 High

   Demonstrated the counterintuitive finding that PKIB enhances rather than only inhibits a PKA-C output, showing PKA-C-dependent Akt Ser473 phosphorylation is promoted by PKIB.

   Evidence In vitro kinase assay with recombinant PKIB and PKA-C plus siRNA knockdown and western blot

   PMID:19483721

   Open questions at the time

   • How an inhibitor of PKA enhances a PKA-C-dependent phosphorylation event is mechanistically unexplained
   • Whether Akt is a direct PKA-C substrate or via an intermediate is unclear
4. 2014 Medium

   Identified a PKA-independent function of PKIB, answering whether the protein acts only through PKA: it binds the GPR39 C-terminus and modulates constitutive Gα13/RhoA/SRE signaling.

   Evidence Yeast two-hybrid screen, co-expression functional assay, and SRE-reporter assay

   PMID:24869658

   Open questions at the time

   • Structural basis of the GPR39 interaction not defined
   • Physiological tissue context of GPR39-PKIB coupling not established
5. 2014 Medium

   Separated PKIB's two activities by mutagenesis, establishing that GPR39 binding and SRE induction are independent of the pseudosubstrate domain required for PKA inhibition.

   Evidence Site-directed mutagenesis of the pseudosubstrate domain with co-expression and SRE-reporter assays

   PMID:24869658

   Open questions at the time

   • Which PKIB region mediates GPR39 binding not mapped
   • Whether the two functions are mutually exclusive in cells not tested
6. 2014 Medium

   Defined a zinc-regulated switch coupling PKIB's two functions: zinc dissociates PKIB from GPR39, freeing it to inhibit PKA and forming a negative-feedback loop.

   Evidence Co-expression with zinc treatment and functional reporter assays

   PMID:24869658

   Open questions at the time

   • Quantitative kinetics of zinc-driven dissociation not measured
   • Endogenous relevance of the feedback loop not shown in native tissue
7. 2015 Medium

   Placed PKIB in a nutrient-responsive pathway in vivo, showing HIF1 induces PKIB under chronic hyperglycemia to suppress beta-cell PKA, with genetic disruption improving islet function.

   Evidence PKIB gene disruption in mice, glucose tolerance testing, and islet pathway analysis

   PMID:25704817

   Open questions at the time

   • Direct HIF1 binding to the PKIB locus not shown in this entry
   • Contribution of the GPR39/Akt arms to the islet phenotype not dissected
8. 2016 Medium

   Placed PKIB functionally upstream of PI3K/Akt in cancer, showing PI3K inhibition abolishes PKIB-driven proliferation and invasion in NSCLC.

   Evidence Gain/loss-of-function with MTT/BrdU, migration/invasion assays, and PI3K inhibitor rescue

   PMID:27325557

   Open questions at the time

   • Direct molecular link from PKIB to PI3K activation not defined
   • Role of PKA inhibition versus Akt activation in the phenotype not separated
9. 2020 Medium

   Extended the PKIB-Akt axis to a physiological invasive process, showing PKIB supports trophoblast migration, invasion, and vessel formation through Akt and downstream MMP2/MMP9/GSK3β.

   Evidence siRNA knockdown, real-time cell analysis, tube formation/sprouting assays, and western blot

   PMID:32676926

   Open questions at the time

   • Whether PKA-C mediates the Akt effect in trophoblasts not tested
   • Upstream regulator of PKIB in trophoblasts unknown
10. 2024 Medium

    Identified GR as an upstream transcriptional driver of PKIB and linked PKIB to nuclear PKA-C/CREB activation in castration-resistant prostate cancer.

    Evidence RNA-seq, western blot, nuclear fractionation, and CREB phosphorylation assays in CRPC models and xenografts

    PMID:38030378

    Open questions at the time

    • Direct GR binding at the PKIB promoter not demonstrated here
    • Reconciliation of nuclear PKA-C accumulation with PKA inhibition not addressed
11. 2025 Medium

    Identified a specific PKA substrate downstream of PKIB and a transcriptional driver, showing PKIB lowers HSP27 phosphorylation to promote bladder cancer and MYCN drives PKIB expression.

    Evidence In vitro proliferation/migration/invasion assays, xenograft, HSP27 phospho-western, and MYCN ChIP on the PKIB promoter

    PMID:40593489

    Open questions at the time

    • Causal chain from reduced HSP27 phosphorylation to invasion not fully mapped
    • Whether MYCN regulation generalizes beyond bladder cancer not tested

• The central paradox of how a PKA pseudosubstrate inhibitor can simultaneously suppress PKA substrate phosphorylation (HSP27) and enhance a PKA-C-dependent output (Akt Ser473), while also redistributing PKA-C to the nucleus, remains mechanistically unresolved.
• No structural model of the PKIB-PKA-C complex coupled to localization control
• No unifying biochemical explanation linking PKA inhibition, nuclear PKA-C accumulation, and Akt activation
• Tissue-specific selection between the GPR39, PKA, and Akt functions not defined